Peripheral serotonin (5HT) has been implicated in migraine and temporomandibular pain disorders in humans and animal models and yet the mechanism(s) by which 5HT evokes pain remains unclear. Trigeminal pain can be triggered by activation of the transient receptor potential V1 channel (TRPV1), expressed by a subset of nociceptive trigeminal ganglia (TG) neurons and gated by capsaicin, noxious heat, and other noxious stimuli. As 5HT is released in the periphery during inflammation and evokes thermal hyperalgesia, and TRPV1 is essential for thermal hyperalgesia, we hypothesized that 5HT increases the activity of capsaicin-sensitive trigeminal neurons and that this increase can be attenuated by pharmacologically targeting peripheral 5HT receptors. TG cultures were pretreated with 5HT (10 nM-100 lM), sumatriptan (5HT 1B/1D agonist), ketanserin (5HT 2A antagonist), granisetron (5HT 3 antagonist), or vehicle prior to capsaicin (30-50 nM). Single-cell accumulation of intracellular calcium was recorded or calcitonin gene-related peptide (CGRP) release was measured following each treatment. In addition, using in situ hybridization and immunohistochemistry, we detected the colocalization of 5HT 1B , 5HT 1D , 5HT 2A , and 5HT 3A , but not 5HT 2C mRNA with TRPV1 in TG cells. 5HT pretreatment evoked a significant increase in calcium accumulation in capsaicin-sensitive trigeminal neurons and enhanced capsaicinevoked CGRP release, but had no significant effect when given alone. Sumatriptan, ketanserin, and granisetron treatment attenuated calcium accumulation and 5HT enhancement of capsaicin-evoked CGRP release. Together these results indicate that 5HT increases the activity of capsaicin-sensitive peripheral nociceptors, which can be attenuated by pharmacologically targeting peripheral 5HT receptors, thereby providing a mechanistic basis for peripheral craniofacial pain therapy. Ó
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Introduction
Approximately 1 in 4 people experience persistent craniofacial pain, such as temporomandibular pain disorders and headache [41, 42] , and approximately 10 million Americans experience debilitating migraine [62], making craniofacial pain one of the most common and poorly controlled pain problems [5] . The monoamine neurotransmitter serotonin (5HT) has been implicated in several pain conditions mediated by the trigeminal system [20, 22, 29, 31] . Several therapeutics being examined in clinical trials predominately target the central serotonergic system to treat migraine [13, 24] and trigeminal neuropathy [34] . As 5HT is pronociceptive in the peripheral nervous system where pain is often initiated, it may be effective to target the peripheral serotonergic system as a therapeutic option. However, the mechanism(s) by which 5HT acts on peripheral sensory neurons to modulate pain remain unclear.
The vast majority of 5HT in the mammalian body is located in peripheral tissues where it can be actively absorbed and released by platelets, mast cells, and immune cells [60] . Noxious stimuli trigger these cells to release proinflammatory mediators, including 5HT. In the trigeminal system, 5HT levels are increased in human masseter muscle associated with pain and allodynia [22, 23] and following temporomandibular joint movement-evoked pain [37] . Additionally, injection of exogenous 5HT evokes hyperalgesia in both humans [4, 20, 22, 23] and animals [46, 65, 66] , which is attenuated by local administration of 5HT receptor antagonists, indicating a modulatory role of 5HT in at least certain pain states.
During the inflammatory process, the activation of the transient receptor potential V1 channel (TRPV1), which is expressed on a major set of trigeminal nociceptors, evokes thermal hyperalgesia. The activation of TRPV1 by thermal stimuli [9,10,15,68], oxidized
